Skip to main content
PFE
NYSE Life Sciences

Padcev-Imfinzi Cuts Bladder Cancer Death Risk 42%; Blackstone Backs Obesity Drug With $1.5B

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$29.12
Mkt Cap
$164.669B
52W Low
$23.62
52W High
$31.44
52W Position info
23% above low
Off High info
7.4% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PFE sits 23% above its 52-week low of $23.62.

Summary

Pfizer's Padcev, paired with AstraZeneca's Imfinzi before surgery, cut death risk 42% versus surgery alone in a nearly 700-patient bladder cancer trial, with two-year survival of 78% versus 69%. Separately, Blackstone-managed funds committed up to $1.5 billion through 2028 to develop the obesity drug berobenatide, with Pfizer keeping control and payments tied to U.S. approval and sales milestones. The same drug showed 15.9% weight loss after 32 weeks in the Phase 2b VESPER-1 extension, with no plateau, while the Phase 3 VESPER-6 monthly-dosing trial is enrolling. Pfizer is also seeking about €1.3 billion from Poland for unpaid COVID-19 vaccine orders, a Brussels court having overturned a seizure of PANSA transit-fee revenue in a ruling that is not final. The pipeline news lands after the Nov. 3 raise of 2026 revenue guidance to $62.0-64.0 billion and adjusted EPS to $2.95-3.05, and the obesity data plus outside funding matter most for the post-COVID growth story.

At the time of this announcement, PFE was trading at $29.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $164.7B. The 52-week trading range was $23.62 to $31.44. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $28.87 info
Change: +$0.0175 (+0.06%) info
Market Cap: $164.498B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.87 info
Change: -$0.580 (-2%) info
Market Cap: $164.498B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $28.87 info
Change: -$1.79 (-6%) info
Market Cap: $164.498B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $28.87 info
Change: -$1.75 (-6%) info
Market Cap: $164.498B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $28.87 info
Change: -$1.86 (-6%) info
Market Cap: $164.498B info